24/7 Market News Snapshot 05 June, 2025 – Scinai Immunotherapeutics Ltd. American Depositary Shares (NASDAQ:SCNI)

June 5, 2025

DENVER, Colo., 05 June, 2025 (www.247marketnews.com) – (NASDAQ:SCNI) are discussed in this article.
Scinai Immunotherapeutics Ltd. (NASDAQ:SCNI) is experiencing a remarkable surge in pre-market trading, with shares climbing to $6.242, representing a staggering 147.70% increase from the previous day’s close of $2.520. This surge is fueled by a trading volume of 5.77 million shares, reflecting heightened investor interest and confidence in the company’s potential. Technical indicators suggest that this bullish momentum may continue, bolstered by the recent progress in Scinai’s immunotherapy initiatives.

In a significant development, Scinai has also announced the receipt of regulatory clearance under the Golden Power regulation for its option to acquire 100% of the share capital of Pincell S.r.l., an Italian biotechnology firm. This clearance follows a thorough review by the Coordination Group for the exercise of special powers, with the endorsement from the Italian Ministry of Health affirming the strategic alignment of the acquisition with Scinai’s goals. This marks an important milestone as it satisfies a key condition set forth in the option agreement signed in March 2025. However, finalization of the acquisition will depend on meeting customary closing conditions.

CEO Amir Reichman expressed enthusiasm for the regulatory approval, viewing it as a critical stride toward the acquisition of Pincell. Pincell’s lead candidate, PC111—a fully human monoclonal antibody targeting the Fas/FasL pathway—holds significant therapeutic promise, particularly for severe dermatological conditions including Pemphigus and Stevens-Johnson Syndrome. The European Medicines Agency has already granted Orphan Drug Designation for PC111, underlining its potential to address unmet medical needs.

As part of its ongoing commitment to innovation, Scinai’s Polish subsidiary has submitted a €12 million grant application under the European Funds for a Modern Economy program to support the advancement of PC111, with an award decision expected later this summer. This strategic move underscores Scinai’s dedication to pioneering biopharmaceutical advancements and its focus on delivering impactful solutions in healthcare.

Related news for (SCNI)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.